Our client faced critical challenges that threatened their market position and regulatory compliance. With heart disease remaining a leading global health concern, their revolutionary non-invasive technology promised a breakthrough – but only if flawlessly implemented.
Their solution addressed a critical market need: traditional heart disease detection methods typically involve invasive procedures that are costly, uncomfortable, and not widely accessible. By pioneering a non-invasive, AI-based approach that could be deployed more broadly and conveniently, our client positioned themselves to transform early diagnosis and treatment – but this opportunity hinged entirely on product reliability.
So, the stakes were high: without proper quality assurance processes, the company risked releasing unreliable medical devices that could undermine trust in their AI-based technology, compromise patient outcomes, and trigger regulatory scrutiny.
Our client needed to establish comprehensive quality assurance protocols for both their hardware cardiograph device and software applications while navigating the complex regulatory landscape of medical technology. Without addressing these challenges, they risked joining the ranks of promising healthcare innovations that never reached their full potential.